Concepedia

Sik-Kwan Chan

SC

3

Publications

131

Citations

3

H-Index

2009

Active since

Affiliations

University of Hong Kong(Current)

Sik-Kwan Chan is an author at University of Hong Kong specializing in cancer therapeutics, health sciences, and oncology.

ORCID

Top concepts

Publications per year

2009–2021

3

Publications

3

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

Véronique Dièras, John A. Glaspy, Adam Brufsky et al. · European Journal of Cancer Supplements · 2009 · 44 citations

, , +9

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Chi‐Leung Chiang, Sik-Kwan Chan, Shing Fung Lee et al. · Cancers · 2021 · 44 citations · Full text

Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes

John M. Nicholls, Victor Lee, Sik-Kwan Chan et al. · British Journal of Cancer · 2019 · 43 citations · Full text

Rows per page

1–3 of 3